Short answer

Spero Therapeutics Inc (SPRO) filed its Q3 2018 10-Q quarterly report on Nov 8, 2018 for the quarter ended Sep 30, 2018.

Spero Therapeutics Inc Q3 2018 10-Q analysis

AI summary of MD&A and risk factor updates

Grant revenue $0.6M, versus $0.5M YoY, with no product sales
Net loss $10.5M vs $9.8M YoY, operating loss $10.9M vs $10.0M
SPR994 R&D $3.2M vs $1.8M, strongest program; Potentiator Platform $1.4M vs $2.8M
Cash, equivalents and securities $131.2M; operating cash outflow $26.1M and marketable-securities purchases $90.4M
Phase 3 SPR994 trial expected around year-end 2018; SPR720 Phase 1 planned early 2019, with funding projected into second half of 2020

Newly triggered regulatory risk: GDPR took effect in May 2018, with potential fines up to €20 million or 4% of global revenue
Most materially updated funding risk: BARDA award added $15.7 million over three years, with remaining funding subject to two options
Clinical risk: SPR994 pivotal Phase 3 trial relies on Japanese Phase 2 data not designed under FDA cUTI guidance
Operational risk: Small number of third-party manufacturers and no long-term agreements create potential supply delays
Financial risk: Net loss reached $31.1 million for nine months ended September 30, 2018, with no product revenue generated

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.